Clene Inc. Common Stock (CLNN)

Price$5.45

Value ScoreF

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-55.32%

Price vs S&P 500 (4W)-25.13%

VGM Score23.85

Market Capitalization$69.64M

All Metrics

Book Value / Share (Quarterly)$0.66

P/TBV (Annual)18.25x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-24.78%

Cash Flow / Share (Quarterly)$-1.54

Price vs S&P 500 (YTD)-15.31%

Gross Margin (TTM)82.84%

Net Profit Margin (TTM)-25009.70%

EPS (TTM)$-3.18

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-3.18

Revenue Growth (5Y)-0.97%

EPS (Annual)$-2.65

ROI (Annual)-123.54%

Gross Margin (Annual)78.50%

Net Profit Margin (5Y Avg)-7979.03%

Cash / Share (Quarterly)$0.50

Revenue Growth QoQ (YoY)-81.48%

ROA (Last FY)-144.35%

Revenue Growth TTM (YoY)-61.71%

EBITD / Share (TTM)$-1.86

ROE (5Y Avg)-1408.09%

Operating Margin (TTM)-15722.39%

Cash Flow / Share (Annual)$-1.71

P/B Ratio16.33x

P/B Ratio (Quarterly)12.65x

Net Income / Employee (Annual)$-331,300

EV / Revenue (TTM)611.25x

Net Interest Coverage (TTM)-8.27x

ROA (TTM)-159.15%

EPS Incl Extra (Annual)$-2.65

Current Ratio (Annual)0.83x

Quick Ratio (Quarterly)1.93x

3-Month Avg Trading Volume0.37M

52-Week Price Return25.87%

Revenue / Employee (TTM)$1,700

Tangible BV / Share (Quarterly)$0.17

P/S Ratio (Annual)348.21x

Asset Turnover (Annual)0.01x

52-Week High$13.50

Operating Margin (5Y Avg)-8926.11%

EPS Excl Extra (Annual)$-2.65

CapEx CAGR (5Y)-36.90%

26-Week Price Return-47.39%

Quick Ratio (Annual)0.80x

13-Week Price Return2.83%

Total Debt / Equity (Annual)1.99x

Current Ratio (Quarterly)1.94x

Enterprise Value$81.91M

Revenue / Share Growth (5Y)11.09%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-22.70%

Revenue / Employee (Annual)$2,500

Inventory Turnover (Annual)0.82x

Pretax Margin (Annual)-13086.50%

Cash / Share (Annual)$0.48

3-Month Return Std Dev107.94%

Gross Margin (5Y Avg)79.00%

Net Income / Employee (TTM)$-424,200

ROE (Last FY)-369.71%

Net Interest Coverage (Annual)-7.67x

EPS Basic Excl Extra (Annual)$-2.65

Receivables Turnover (TTM)6.25x

Total Debt / Equity (Quarterly)6.36x

EPS Incl Extra (TTM)$-3.18

Receivables Turnover (Annual)6.25x

ROI (TTM)-117.21%

P/S Ratio (TTM)519.71x

Pretax Margin (5Y Avg)-7990.97%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.04

Price vs S&P 500 (52W)1.50%

Year-to-Date Return-7.16%

5-Day Price Return-10.80%

EPS Normalized (Annual)$-2.65

ROA (5Y Avg)-93.15%

Net Profit Margin (Annual)-13086.50%

Month-to-Date Return-16.92%

Cash Flow / Share (TTM)$-0.43

EBITD / Share (Annual)$-2.19

Operating Margin (Annual)-11541.50%

LT Debt / Equity (Annual)0.53x

ROI (5Y Avg)-195.19%

LT Debt / Equity (Quarterly)1.66x

EPS Basic Excl Extra (TTM)$-3.18

P/TBV (Quarterly)2.76x

P/B Ratio (Annual)2.84x

Inventory Turnover (TTM)0.35x

Pretax Margin (TTM)-25009.70%

Book Value / Share (Annual)$2.09

Price vs S&P 500 (13W)-5.42%

Beta0.99x

Revenue / Share (TTM)$0.01

ROE (TTM)-322.23%

52-Week Low$3.25

vGradeF

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.27est. -0.65

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.08

4.09

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CLNNClene Inc. Common Stock	F	F	C	$5.45
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Clene Inc is a clinical-stage pharmaceutical company developing novel clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases. The company uses its proprietary electro-crystal-chemistry platform to produce concentrated, stable nanocrystal suspensions. It operates a dietary supplements business with products including CNM-Au8, CNM-ZnA, and CNM-AgZn17.